Rankings
▼
Calendar
ALGS Q1 2025 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
ALGS
Aligos Therapeutics, Inc.
$45M
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$311,000
-68.5% YoY
Gross Profit
$311,000
100.0% margin
Operating Income
-$19M
-6187.5% margin
Net Income
$43M
13854.7% margin
EPS (Diluted)
$-2.11
QoQ Revenue Growth
-50.6%
Cash Flow
Operating Cash Flow
-$21M
Free Cash Flow
-$21M
Stock-Based Comp.
$959,000
Balance Sheet
Total Assets
$151M
Total Liabilities
$34M
Stockholders' Equity
$116M
Cash & Equivalents
$74M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$311,000
$986,000
-68.5%
Gross Profit
$311,000
$986,000
-68.5%
Operating Income
-$19M
-$22M
+12.7%
Net Income
$43M
-$35M
+223.6%
← FY 2025
All Quarters
Q2 2025 →